GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Trxade Health Inc (NAS:MEDS) » Definitions » Peter Lynch Fair Value

Trxade Health (Trxade Health) Peter Lynch Fair Value : N/A (As of May. 28, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Trxade Health Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for Trxade Health's Peter Lynch Fair Value or its related term are showing as below:



MEDS's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 1.34
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Trxade Health Peter Lynch Fair Value Historical Data

The historical data trend for Trxade Health's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trxade Health Peter Lynch Fair Value Chart

Trxade Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Trxade Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Trxade Health's Peter Lynch Fair Value

For the Pharmaceutical Retailers subindustry, Trxade Health's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trxade Health's Price-to-Peter-Lynch-Fair-Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Trxade Health's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Trxade Health's Price-to-Peter-Lynch-Fair-Value falls into.



Trxade Health Peter Lynch Fair Value Calculation

Trxade Health's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *-15.244
=N/A

Trxade Health's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.24.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Trxade Health  (NAS:MEDS) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

Trxade Health's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=5.65/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Trxade Health Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Trxade Health's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Trxade Health (Trxade Health) Business Description

Traded in Other Exchanges
N/A
Address
2420 Brunello Trace., Lutz, FL, USA, 33558
Trxade Health Inc is a health service IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey, and patient engagement in the U.S. Its product and services include Integra Pharma Solutions, LLC, Community Specialty Pharmacy, LLC, Delivmeds.com, Bonum Health Hub and Application, and others. its business is classified into reportable segments which are Trxade, Inc, Community Specialty Pharmacy, LLC, Integra Pharma, LLC, and Other, and the majority of the revenue comes from Trxade, Inc.
Executives
A. Jeffrey Newell director 645 CAMP DIXIE RD, PASCOAG RI 02859
Donald G. Fell director 17537 DARBY LANE, LUTZ FL 33558
Janet Huffman officer: CFO, PAO, PFO 5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232
Michael L Peterson director 17 CANARY COURT, DANVILLE CA 94526
Christine L. Jennings director 3840 LAND O' LAKES BLVD., LAND O' LAKES FL 34639
Prashant Patel director, 10 percent owner, officer: President 17537 DARBY LANE, LUTZ FL 33558
Pamela Tenaerts director PO BOX 15012, SARASOTA FL 34277
Gary Augusta director 700 NORTH BRAND BLVD., SUITE 1400, GLENDALE CA 91203
Howard A. Doss officer: CFO 17537 DARBY LANE, LUTZ FL 90067
Surendra K Ajjarapu director, 10 percent owner, officer: CEO 8604 BUTTON BUSH CT, TAMPA FL 33647
Donald V. Almeida director 1115 GUNN HIGHWAY, SUITE 202, ODESSA FL 33556
Charles L Pope director 4902 EISENHOWER BOULEVARD, TAMPA FL 33634
Sandhya Ajjarapu 10 percent owner 17537 DARBY LANE, LUTZ FL 33558

Trxade Health (Trxade Health) Headlines

From GuruFocus